AMRI Promotes Two Company Executives to Key Positions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Albany Molecular Research (AMRI) Updates FY15 Guidance Following Gadea Pharma Acquisition
September 15, 2015 7:04 AM UTCFollowing the acquisition of Gadea Pharmaceutical Group, AMRI (Nasdaq: AMRI) has updated guidance for full year 2015.
"We are very pleased to provide our updated outlook for 2015 results which reflect the recent addition of Gadea Pharmaceutical Group," said William S. Marth, AMRI's president and chief executive officer. "Gadea brought us over 90 technically complex API programs, greatly enhancing our commercial portfolio and opportunities for expanded business. With Gadea's strong EBITDA and margins, combined with our expanding base business, we remain confident in our outlook which includes full year contract revenue growth of over 50%... More
